Can-Fite BioPharma (NYSEMKT:CANF) announces that is has manufactured a supply of Namodenoson for Israeli liver cancer patients under compassionate use at the Rabin Medical Center in Petah Tikva.
Compassionate use allows access to investigational drugs for patients with no other viable treatment options.
Shares are up 6% premarket on light volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.